An interventional study of Microbiological sampling (swab collection) in Infective Endocarditis (IE), sponsored by University Hospital, Clermont-Ferrand. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science
Among 47 studies in Endocarditis with a site in France — 13 open to participants now, 15 under way, 1 of them phase 3. Endocarditis · France.
Among the 47 studies in Endocarditis with a site in France, this one is the 16th largest by planned enrollment of the 28 interventional ones, is one of 4 that started in 2026, is one of 20 with no phase, reaches primary completion later than 12 of the 14 other live ones, and was the 45th registered.
173 studies on the registry are indexed under Endocarditis; 57 are open to participants now.
This study's planned enrollment of 90 is close to the median of 92 across 86 interventional studies indexed under Endocarditis.
Browse Endocarditis studies →13 of the 47 studies in Endocarditis with a site in France are open now, in 1 country. Each count lists the studies.
Of the 38 Endocarditis studies recruiting now, 34 (89%) set no upper age limit and 1 (3%) stop at 75 or younger; 1 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →47 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 4 started in 2026.
Median enrollment 144 across the 28 interventional studies, 269 across the 19 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
1 of 47 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 179 are open to participants now.
University Hospital, Clermont-Ferrand has 2 studies filed under Endocarditis — fewer than ten, so there is no comparison to draw.
5 of the studies in Endocarditis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05146180Centre Henri BecquerelInterest of Parametric Positron Emission Imaging in the Diagnosis of Infections on Cardiac Valve Prosthesis | 2026-12-01 |
| NCT03272724Central Hospital, Nancy, FranceFrench National Observatory on Infective Endocarditis | 2026-12-31 |
| NCT05253469Centre Cardiologique du NordInfective Endocarditis Surgery Using Conventional Prosthetic Valves Versus Cryopreserved Aortic Homograft | 2027-03-30 |
| NCT05989152Assistance Publique - Hôpitaux de ParisEvolution of PET Fixation With FDG at the End of Antibiotic Treatment of Infective Endocarditis on Valvular Prosthesis | 2027-06 |
| NCT07029295Assistance Publique - Hôpitaux de ParisEvaluation of the Impact of a Patient Education Protocol on the Quality of 18F-FDG PET Imaging Indicated for Investigation of Cardiac Inflammation | 2027-08-31 |
Among the 47 studies in Endocarditis with a site in France, from their registry updates:
Enterococci are pathobionts of the human intestinal microbiota: they colonize the gastrointestinal tract as well as the skin, urine, wounds, bile, the oral cavity and endodontic canal, and medical devices (urinary catheters, venous catheters, etc.). They are responsible for urinary, dental, bloodstream, endocardial, biliary, and gastrointestinal infections.
Enterococcus faecalis is the enterococcus most frequently isolated from clinical specimens. It is the third leading cause of infective endocarditis (infection of the cardiac valves) and the leading cause of endocarditis following TAVI (transcatheter aortic valve implantation via the femoral route). E. faecalis infective endocarditis (EFIE) is severe and difficult to treat, with a particularly high relapse rate despite appropriate antibiotic therapy.
Cardiac valve contamination is always secondary to E. faecalis bacteremia, particularly in cases of isolated E. faecalis bacteremia (EFIB), defined by the absence of an identifiable portal of entry. Once in the bloodstream, the bacterium adheres to the valvular endothelium (healthy or damaged) through specific virulence factors, including endocarditis- and biofilm-associated pili (ebp), the collagen adhesin Ace, and aggregation substance (Agg).
The classical portals of entry for EFIE are infections of the urinary tract and the gastrointestinal tract. However, despite extensive investigations, the source of infection remains unidentified in more than 50% of cases. An imbalance of the intestinal microbiota, leading to overgrowth and subsequent translocation of E. faecalis from the digestive tract into the bloodstream, could explain the absence of an identifiable portal of entry during routine clinical and paraclinical evaluations. This plausible hypothesis remains largely unexplored to date. A better understanding of the underlying pathophysiology-particularly gut dysbiosis and the pathogen's capacity for intestinal translocation-could improve the prevention of EFIE occurrence and relapse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collection of four swabs (two rectal swabs, one oral swab, and one skin swab from the inguinal fold).
Biological: Microbiological sampling (swab collection)
Collection of a single rectal swab.
Biological: Microbiological sampling (swab collection)
Participants in the case group will undergo microbiological sampling consisting of four swabs: two rectal swabs, one oral swab, and one skin swab from the inguinal fold. Participants in the control group will undergo a single rectal swab. The samples will be collected for microbiological analysis.
Qualitative and quantitative bacterial composition of the intestinal microbiota (molecular microbiology/PCR).
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Mapping of E. faecalis colonization (urinary, digestive, and/or cutaneous) in patients diagnosed with E. faecalis bacteremia (EFIB);
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Genomic characterization through core genome analysis of E. faecalis strains isolated from colonization sites and from blood cultures in the same patient diagnosed with EFIB;
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Whole-genome characterization of E. faecalis strains isolated from colonization sites and those recovered from blood cultures in patients with EFIB;
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Description of potential portals of entry for enterococci at the end of hospitalization for EFIB.
Time frame: From enrollment to the collection of the four swabs: 24 to 48 hours.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.
Of 34 interventional studies with no phase under Endocarditis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 59. This study's planned 32 months is close to that.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Apr 2026, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →